Conditioning regimen
| Regimen . | Bone marrow recipients (%) (n = 166) . | PBPC recipients (%) (n = 163) . |
|---|---|---|
| TBI plus chemotherapy | ||
| Cyclophosphamide | 96 (58) | 101 (62) |
| Etoposide | 2 (1) | 1 (1) |
| Cyclophosphamide plus etoposide | 8 (5) | 3 (2) |
| Melphalan | 1 (1) | |
| Etoposide plus melphalan | 1 (1) | |
| Chemotherapy alone | ||
| Busulfan plus cyclophosphamide | 54 (33) | 55 (34) |
| Busulfan plus cyclophosphamide plus etoposide | 3 (2) | 2 (1) |
| Busulfan plus melphalan | 1 (1) | 1 (1) |
| Regimen . | Bone marrow recipients (%) (n = 166) . | PBPC recipients (%) (n = 163) . |
|---|---|---|
| TBI plus chemotherapy | ||
| Cyclophosphamide | 96 (58) | 101 (62) |
| Etoposide | 2 (1) | 1 (1) |
| Cyclophosphamide plus etoposide | 8 (5) | 3 (2) |
| Melphalan | 1 (1) | |
| Etoposide plus melphalan | 1 (1) | |
| Chemotherapy alone | ||
| Busulfan plus cyclophosphamide | 54 (33) | 55 (34) |
| Busulfan plus cyclophosphamide plus etoposide | 3 (2) | 2 (1) |
| Busulfan plus melphalan | 1 (1) | 1 (1) |